

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
07 December 2024 :: Issue 778
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Polio – PHEIC

Polio this week – 04 December 2024

Headlines

:: Poliovirus detections in European Region underscore importance of vaccination and vigilance. Poliovirus has been detected through routine surveillance of wastewater systems in three countries in the WHO European Region (Germany, Poland and Spain) since September this year. While no cases have been detected to date, the presence of the virus underscores the importance of vaccination and surveillance, as well as the ongoing risk that any form of poliovirus poses to all countries everywhere. [More](#).

:: The latest report of the International Health Regulations (IHR) Polio Emergency Committee has been published, following the group's meeting last month. The report is available [here](#).

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: six WPV1 cases and 24 WPV1-positive environmental samples
- Algeria: one cVDPV2-positive environmental sample
- Nigeria: one cVDPV2-positive environmental sample

.....

Statement of the fortieth meeting of the Polio IHR Emergency Committee

3 December 2024 *Statement*

[Limited excerpts]

The fortieth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 6 November 2024 with Committee members and advisers meeting via video conference with affected countries, supported by the WHO Secretariat. T

The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV) in the context of the global target of interruption and certification of WPV1 eradication by 2027 and interruption and certification of cVDPV2 elimination by 2029. Technical updates were received about the situation in Afghanistan, Cameroon, France, Ghana, Indonesia, Nigeria, occupied Palestinian territory (oPt), Pakistan, Spain and Zimbabwe.

Wild poliovirus

Since the last Emergency Committee meeting, 51 new WPV1 cases were reported – 17 from Afghanistan and 34 from Pakistan – bringing the total to 62 in 2024. This represents a 283% increase in paralytic cases in Afghanistan and a 550% increase in Pakistan compared to all of 2023. The number of WPV1 positive environmental samples in Pakistan in 2024 is 402 compared to 126 during all of 2023. The number of WPV1 positive environmental samples in Afghanistan in 2024 is 84 compared to 62 in all of 2023...

Circulating vaccine derived poliovirus (cVDPV)

In 2024, there have been 190 cVDPV cases, of which 182 are cVDPV2 and eight are cVDPV1. Additionally, 177 environmental samples were positive for cVDPV, all type 2. Of the 182 cVDPV2 cases

in 2024, 85 (46%) have occurred in Nigeria. Of the eight cVDPV1 cases in 2024, seven were reported from DR Congo and one from Mozambique.

A total of 529 cases have been confirmed with cVDPV in all of 2023, of which 395 are cVDPV2 and 134 are cVDPV1. Of the 529 cVDPV cases reported in 2023, 226 (43%) have occurred in the DR Congo. Since the last meeting of the Emergency Committee, Cameroon, Djibouti, French Guiana (France), Ghana, oPt, Spain, and Zimbabwe reported new cVDPV2 detections...

The Committee noted that much of the risk for cVDPV outbreaks can be linked to a combination of inaccessibility, insecurity, a high concentration of zero dose and under-immunized children along with continued population displacement. These factors are currently most evident in northern Yemen where response immunization has not yet happened due to insecurity and conflict as well as northern Nigeria, south-central Somalia, eastern DR Congo and oPt...

Conclusion

The Committee unanimously agreed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC) and recommended the extension of Temporary Recommendations for a further three months...

Additional considerations

The Committee noted that GPEI Polio Oversight Board (POB) in its recent meeting in mid-October 2024, revised the timeline for the GPEI Strategy 2022 – 2026, up to 2029. The strategy under the revised timeline, aims to stopping WPV1 transmission in Pakistan and Afghanistan by end-2025 and certification of WPV1 eradication by end-2027; and stopping cVDPV2 outbreaks globally by end-2026 and certification cVDPV2 elimination by 2029. The bOPV Cessation will be considered after certification of eradication of WPV1 and certification of elimination of cVDPV2 by the Global Certification Commission on Poliomyelitis Eradication.

The Committee expressed concern about the intensifying WPV1 transmission in Afghanistan and Pakistan with significant increase in the number of paralytic cases and geographic spread in 2024. Consequent to persistent WPV1 transmission, the YB3A genetic cluster of WPV1 has split into two, indicating **significant number of under-immunized children in both the remaining endemic countries.** Continuing WPV1 transmission despite the ongoing campaigns implementation indicates the need for an in-depth programme review and adjustment in current programme strategies. The review should inform the programme planning and implementation in the crucial upcoming low transmission season from December 2024 through May 2025.

The Committee is concerned about the inability to implement house-to-house campaigns and very low engagement of women health workers in Afghanistan, putting infants and young children especially the girls, at high risk of missing polio vaccination. **This situation may jeopardize all the gains made in Afghanistan over the last two years,** including in the East Region where polio epidemiology has been seemingly improving during the last few months...

Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, the Director-General accepted the Committee's assessment, and on 3 December 2024 determined that the poliovirus situation continues to constitute a Public Health Emergency of International Concern (PHEIC) with respect to WPV1 and cVDPV.

.....
.....

mPox – PHEIC

<https://www.who.int/emergencies/situations/mpox-outbreak>

News, Announcements

Surveillance, case investigation and contact tracing for mpox: interim guidance, 27 November 2024

6 December 2024

Overview

This is an updated version of the interim guidance for surveillance, case investigation and contact-tracing for mpox published on 20 May 2024. It applies to all countries.

The overall goal of surveillance, case investigation and contact tracing for mpox is to detect new outbreaks and stop transmission, protect people at risk in endemic and new settings, and make progress towards elimination of human-to-human transmission of mpox...

Safety monitoring of mpox vaccines using cohort event monitoring: a WHO protocol

3 December 2024

Synopsis

Study title

Safety monitoring of mpox vaccines using cohort event monitoring: a WHO study

Background and rationale

Vaccines approved for use in national immunization programmes (NIPs), are considered safe and efficacious based on demonstrable evidence from randomized controlled clinical trials. They are, however, not completely free of risks, and occasional adverse events will inevitably occur following vaccination at the population level.

Given vaccines are often recommended for otherwise healthy individuals, the key to success for NIPs is public trust in vaccine safety. Thus, systematic vaccine safety surveillance is indispensable for ensuring safety of vaccines and public trust. Pharmacovigilance has an important role to provide further evidence on the safety of mpox vaccines in the general population. Safety monitoring of mpox vaccines should start simultaneously with the implementation plans for immunization with mpox vaccines.

This protocol describes a cohort event monitoring (CEM) study designed to capture adverse events occurring in a cohort of individuals vaccinated with mpox vaccines during routine clinical practice for the purpose of signal detection...

.....
.....

Pandemic Accord

Twelfth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response

Resumed 02.12.2024- 06.12.2024

No news release summarizing progress or next steps of this resumed sessions was identified. Short video segments from each of the days is available [here](#).

.....

IFPMA Statement - Resumed 12th session of the Intergovernmental Negotiating Body (INB 12)

Statement 2 Dec 2024

On 2 December 2024 in Geneva, IFPMA delivered a statement at the resumed INB 12.

The innovative pharmaceutical industry remains committed to achieving a pandemic agreement that works, addressing societal needs while enabling the private sector to innovate and respond effectively to future pandemics.

A multi-stakeholder approach is key for managing pandemics effectively. Our industry recognizes that it has a key role to play in pandemic preparedness and response, alongside partners. The pandemic treaty provides a unique opportunity to clarify roles and responsibilities and elaborate how stakeholders can depend on one another to achieve a better outcome in the next pandemic.

To strengthen equitable access, Member States need to address key obstacles such as insufficient funding for procurement in low-income countries, poor demand forecasting, regulatory challenges, limited absorption capacity, and export restrictions.

Our industry also has an important role to play in equitable access, alongside its role in driving the innovation that will create the pharmaceutical products needed to respond to the next pandemic outbreak.

A strong intellectual property system is essential for enabling that innovation. Industry has committed to expanding access to its products during a pandemic through a range of options, such as donations, tiered pricing, voluntary sub-licensing, and technology transfers on mutually agreed terms.

We recognize that resumed INB 12 is another important session in the negotiations of the pandemic agreement, and we remain committed to sharing our experience and providing our expertise to support this process.

.....
.....

Gavi

Gavi Board approves measures to support sustainability of vaccine programmes and boost access in vulnerable communities

- Gavi's Board approved a series of measures aimed at strengthening countries' abilities to sustain their own immunisation programmes and improve access to vaccines in fragile countries and settings
 - Meeting took place amid unprecedented demand for vaccines in Gavi Implementing countries
- Geneva, 5 December 2024 – The Board of Gavi, the Vaccine Alliance today approved a series of decisions that will help countries to sustain their own immunization programs and close equity gaps in the most vulnerable communities. The decisions were taken amid global demand for vaccines from Gavi-implementing countries...

...2024 saw a rise in the number of zero-dose children in Gavi countries, largely driven by ongoing humanitarian and health crises, an increase in disease outbreaks driven partly by climate change and macroeconomic challenges in some Gavi supported countries, placing at risk their abilities to sustain immunisation programmes...

"Against a backdrop of historic progress, decisions taken by our Board today reflect a collective commitment of our partners to strengthen immunisation systems, tackle health inequities and place countries firmly on the path to sustainable transition," said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. "As we prepare for our next strategic period starting in 2026, we must continue to innovate to address the new challenges we face and achieve the goal of protecting people, communities and our world from preventable disease."...

Support for sustainability

Signaling its commitment to helping countries on their pathway towards transitioning away from Gavi support while acknowledging the macroeconomic headwinds many countries are facing, **the Board approved changes to Gavi's transition, eligibility and co-financing model.** These changes will see Gavi implement targeted measures for countries in various stages of transition related to co-financing, eligibility thresholds and access to Gavi support, as well as duration of support.

Building on lessons learned from the MICs approach that was first implemented in 2022, **the Board also agreed that Gavi will integrate catalytic support for lower middle-income countries and International Development Association (IDA)-eligible countries into Gavi's broader co-financing model.** This support will facilitate the introduction of the following high impact vaccines: HPV, PCV and rotavirus, and potential support for dengue and TB vaccines – taking into account the burden and potential for public health impact in middle-income countries.

Addressing fragility

Recognising the impact of conflict and climate change on immunisation, **the Board approved additional flexibility to support fragile countries, including the possibility of multi-year co-financing waivers for countries grappling with long-term, large-scale conflict** as well as a special package of support for Small-Island Developing States (SIDS). This latter package seeks to help build resilience against the challenges SIDS grapple with including climate change and an increasing number of natural disasters that lead to a heightened risk of outbreaks and costly emergency response.

Strengthening health systems

Health systems are critical for equitable provision of immunisation and other vital health services. In recognition of their importance, and the added complexity that comes with an expanded portfolio of vaccines, the Gavi Board approved changes to the health systems policy for its next strategic period, "Gavi 6.0" which begins in 2026.

The revised policy will see consolidated cash grants allocated to countries and a new grant allocation formula that will help ensure that those with greatest need receive adequate support, while also safeguarding vulnerable populations living in fragile settings. In alignment with the goals of the Lusaka agenda, these measures will enhance efficiency, foster greater country ownership of immunisation programmes, in addition to encouraging domestic investments in health systems and cold chain.

A framework for demand

With Gavi-implementing countries aiming for a record number of new vaccine introductions for 2024 and 2025, alongside high demand for other types of Gavi support, **the Board approved an evidence-informed framework to guide Gavi's resource allocation to countries to drive the most impact** - to be used in the unlikely event that adjustments to currently planned activities are necessary. The unprecedented demand for vaccines further underlines the importance of Gavi's replenishment process for Gavi 6.0 which was launched in June this year at the Global Forum for Vaccine Sovereignty and Innovation, co-hosted by France, the African Union with Team Europe and will culminate in a pledging event in early 2025 with a goal to raise at least US\$9 billion from donors.

Appointments and process updates

- Ana de Pro Gonzales was appointed as an Unaffiliated Board Member and as a member of the Audit and Finance Committee
- Anna Sedgeley was appointed as an Unaffiliated Board Member and as a member of the Governance Committee:
- Anne Schuchat was reappointed as Chair of the Programme and Policy Committee

.....

European Union and the Bill & Melinda Gates Foundation to co-host Gavi High Level Pledging Summit

BRUSSELS (5 December 2024) – The European Union and the Gates Foundation, together with the close support of other Gavi donors and implementing countries, will co-host the Gavi 6.0 pledging Summit. The event is planned to take place in Brussels late in the first quarter of 2025. It will bring

together global leaders from government, partner organisations, vaccine manufacturers, civil society and the private sector, to secure crucial investments in vaccination programmes.

President of the European Commission, Ursula von der Leyen said: "In today's world, addressing health challenges at the global level is more important than ever. Vaccines have a lifesaving power. And Gavi's role is key for making equitable vaccine access a reality, and for empowering our partners to achieve health sovereignty. Together with Gavi, we have the goal to vaccinate 500 million children by 2030. That is why the European Union is proud to co-host Gavi's High Level Pledging Summit in Brussels. Our support will remain steadfast."...

José Manuel Barroso, chair of the Board of Gavi, said "By investing in Gavi, our donors are investing in a world that is more resilient to disease outbreaks, in economies that are more capable of contributing to global growth and in the future of over half of the world's children, whose ability to lead healthy, productive lives is so vital for the future of our planet. I am deeply grateful to our co-hosts, the European Union and the Gates Foundation, for their leadership and commitment to building a future that is safer, healthier and more prosperous for all."...

.....
.....

Türkiye – Financing for Vaccines Production, Public Health Emergencies

World Bank Approves \$250 Million for Türkiye to Improve Preparedness for Public Health Emergencies

WASHINGTON, December 5, 2024 – The World Bank Board today approved \$250 million in financing to improve readiness for and handling of public health emergencies in Türkiye.

The Türkiye Preparedness for Public Health Emergencies Project will help expand vaccine production and strengthen the country's capacity to detect and initiate a rapid response to public health emergencies. The project will support vaccine production by financing equipment and technical assistance. Emergency preparedness will cover public health risks stemming from a range of sources, given the country's susceptibility to risks from infectious diseases, climate change and natural disasters.

The project will benefit the entire population of Türkiye through increased access to domestically produced vaccines over the long term, as well as through improved disease surveillance and strengthened capacity for emergency response. These efforts will help prevent the spread of infectious diseases and curb public health risks which will have positive health, economic and social impacts.

"Türkiye has made significant strides in the health sector, enhancing access to affordable healthcare and improving health outcomes through a well-functioning primary healthcare network. This operation will enhance the country's resilience by strengthening public sector capacity to contain disease outbreaks and to effectively plan response and risk communication for public health emergencies. The World Bank is delighted to support Türkiye's efforts to protect its people from new and emerging public health risks, such as global pandemics," said Humberto Lopez, World Bank Country Director for Türkiye...

.....
.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

[:: Organization Announcements](#)
[:: Journal Watch](#)
[:: Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 07 Dec 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

5 December 2024 *News release*

WHO announces first prequalification of a tuberculosis diagnostic test

The World Health Organization (WHO) has granted prequalification to the molecular diagnostic test for tuberculosis (TB) called Xpert® MTB/RIF Ultra. It is the first test for TB diagnosis and antibiotic susceptibility testing that meets WHO's prequalification standards...

"This first prequalification of a diagnostic test for tuberculosis marks a critical milestone in WHO's efforts to support countries in scaling up and accelerating access to high-quality TB assays that meet both WHO recommendations and its stringent quality, safety and performance standards," said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products. "It underscores the importance of such groundbreaking diagnostic tools in addressing one of the world's deadliest infectious diseases."...

3 December 2024 *Statement*

Statement of the fortieth meeting of the Polio IHR Emergency Committee

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 06 December 2024

WHO supports Democratic Republic of the Congo reinforce efforts to diagnose disease in remote area

:: 06 December 2024

Sierra Leone launches Ebola vaccination drive for frontline health workers

:: 03 December 2024

Maintaining essential health services amid mpox outbreak response

:: 01 December 2024

Multi-month HIV treatment dispensing improves care in Rwanda

WHO Region of the Americas PAHO

:: 4 Dec 2024

New report reveals urgent need for targeted programs that address violence against Indigenous and Afro descendent women and girls in the Americas

Washington D.C. December 4, 2024 (PAHO) – A new report into violence against Indigenous and Afro descendent women and girls, launched today by the Pan American Health Organization (PAHO), calls on countries of the Americas and partner organizations to urgently improve information and strengthen the implementation of programs that address the...

:: 2 Dec 2024

El Salvador joins the Alliance for Primary Health Care in the Americas

Washington DC, December 2, 2024 (PAHO) - The Ministry of Health of El Salvador (MINSAL) has joined the Pan American Health Organization (PAHO), the Inter-American Development Bank (IDB) and

the International Bank for Reconstruction and Development (World Bank) through the establishment of the Mesa Consultiva of Primary Health Care (PHC) in El...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 5 December 2024 *Media release*

[Up to 1 in 5 households in Europe experience catastrophic spending because of health-care costs, new WHO digital platform shows](#)

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[5 December 2024 | Oropouche virus disease - Region of the Americas](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 49, pp. 719–740 6 December 2024

PDF: <https://iris.who.int/bitstream/handle/10665/379717/WER9949-eng-fre.pdf>

:: Meeting of the Strategic Advisory Group of Experts on Immunization, September 2024: conclusions and recommendations

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

7 December 2024

[WHO global action plan on promoting the health of refugees and migrants, 2019–2030](#)

6 December 2024

[Master protocol for surveillance of pfhrp2/3 deletions and biobanking to support future research, second...](#)

6 December 2024

[Surveillance template protocol for pfhrp2/pfhrp3 gene deletions, second edition](#)

6 December 2024

[Response plan to pfhrp2 gene deletions, second edition](#)

6 December 2024

[Surveillance, case investigation and contact tracing for mpox: interim guidance, 27 November 2024](#)

6 December 2024

[Psychological first aid during Ebola virus disease outbreaks, 2nd edition](#)

4 December 2024

[Generating research and evidence for impact: sexual and reproductive health and rights](#)

4 December 2024

[Implementing the integrated sentinel surveillance of influenza and other respiratory viruses of epidemic...](#)

3 December 2024

[Global surveillance and monitoring system for substandard and falsified medical products: activity report...](#)

3 December 2024

[Safety monitoring of mpox vaccines using cohort event monitoring: a WHO protocol](#)

2 December 2024

[Implementing WHO evidence-based interventions for adolescents and young adults living with and affected by HIV](#)

December 2024

[Pandemic influenza preparedness framework: partnership contribution high-level implementation plan III...](#)

1 December 2024

.....

.....

USA – HHS, FDA, CDC

HHS

News

[HHS Announces New Global Strategy to Promote Innovation, Cooperation, and Equity](#)

December 5, 2024 *News Release*

Today, the U.S. Department of Health and Human Services (HHS), through the Office of Global Affairs (OGA), launched a new Global Strategy that expands the Department's focus, in the wake of the COVID-19 pandemic, from not only responding to disease and outbreaks but increased emphasis on improving foundational support and proactively making communities healthier. Through international collaborations and initiatives, HHS can leverage U.S. scientific and technological expertise alongside key learnings from our global partners to improve health outcomes for a more-well society...

"HHS is committed to embedding equity as a foundational component of health and supporting communities in the U.S. and abroad that have been historically underserved," said Assistant Secretary of Global Affairs Loyce Pace. "We cannot have a healthy country without a healthy world, and a healthy world requires advancing health for everyone." This strategy is comprised of three main goals:

1. Advancing United States interests and leadership in health, human services, and security through international policy;
2. Leveraging technical expertise in science, technology, and practice through partnership to improve global health, well-being, and health access; and
3. Protecting and promoting the health and well-being of all Americans through international preparedness and response...

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

Vaccines and Related Biological Products Advisory Committee December 12, 2024 Meeting Announcement - 12/12/2024

:: Meeting Information

:: Event Materials

CDC/ACIP [U.S.] [to 07 Dec 2024]

<http://www.cdc.gov/media/index.html>

Latest News

No new digest content identified.

ACIP Meetings

Next ACIP Meeting

February 26-27, 2025

MMWR Weekly

<https://www.cdc.gov/mmwr/index2024.html>

December 5, 2024 / No. 48

PDF of this issue

- Updated Recommendation for Universal Hepatitis B Vaccination in Adults Aged 19–59 Years — United States, 2024
- Notes from the Field: Rollout of Nirsevimab to Protect Infants and Young Children During the Respiratory Syncytial Virus Season — New York City, 2023–2024

.....

.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 December 2024

Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
6 December 2024

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Public health guidance

[Reporting Protocol for integrated respiratory virus surveillance](#)

4 Dec 2024

This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.

Surveillance and monitoring

[COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in eight European countries in the VEBIS monitoring network - October 2023 to April 2024](#)

3 Dec 2024

This document reports the results of prospective monitoring of COVID-19 vaccine effectiveness.

.....
.....

Africa CDC [to 07 Dec 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

[Statement on the Continental Secretariat of the Lusaka Agenda](#)

Johannesburg, South Africa | Addis Ababa, Ethiopia, 3 December – The launch of the Continental Secretariat of the Lusaka Agenda, hosted by Africa CDC, marks **a critical step in transforming healthcare across Africa**. The Secretariat will coordinate implementation and accountability mechanisms to advance the Agenda's objectives...

Dr Jean Kaseya, Africa CDC Director General, elaborated: "The Lusaka Agenda Secretariat, housed at Africa CDC, will work with partners to develop the Lusaka Agenda Monitoring and Accountability Framework and a continental scorecard for timely reporting to AU Heads of State. Through the Secretariat, AU Member States will better leverage global health initiatives to complement domestic financing, maximising health impacts in support of country-led priorities."

The Secretariat will drive five strategic shifts to transform Africa's health systems and shape the evolution of Global Health Initiatives (GHIs):

- :: strengthening primary healthcare (PHC) as the foundation of resilient health systems,
- :: fostering sustainable financing through domestic investments,
- :: advancing health equity,
- :: ensuring strategic coherence across programmes, and
- :: coordinating research, development, and regional manufacturing to address global health gaps.

By prioritising these shifts, PHC will anchor Africa's preparedness, prevention, and response to public health challenges. **President Ramaphosa affirmed: "The Lusaka Agenda is a political commitment endorsed by African Heads of State to achieve health equity and strengthen primary healthcare across the continent.** I call on all stakeholders to support Africa CDC's leadership and fully commit to the accountability framework, ensuring transparency and measurable progress toward a healthier, more resilient Africa."

News

National Borders a Critical Frontline in Containing Deadly Infections

2 December 2024

...The Strategic Framework for Strengthening Cross-Border Surveillance and Information Sharing, developed by Africa CDC, provides **a comprehensive blueprint** for mitigating these challenges and safeguarding the continent's health security.

It recognises that **Africa, with its high levels of cross-border movement and porous borders, faces unique challenges in managing public health threats**. Yet points of entry (PoEs), such as airports, seaports and ground crossings, are often ill-equipped to handle public health threats, posing significant risks to regional and global health security...

Key Strategies for Implementation

The framework identifies six strategic pillars as foundational to its success:

:: The first pillar focuses on coordination and collaboration, advocating for the establishment of cross-border health committees and multi-sectoral partnerships. These mechanisms are designed to harmonise national and regional efforts, ensuring a cohesive response to health threats.

:: The second pillar emphasises capacity building at PoEs, highlighting the need for improved infrastructure, training, and resources. This includes developing standard operating procedures and providing ongoing professional development for border health staff.

:: Data sharing and operational research form the third pillar, emphasising harmonising reporting protocols and leveraging digital technologies. Real-time data exchange is critical for timely decision-making and effective resource allocation.

:: The fourth pillar aims to strengthen laboratory and surveillance systems at PoEs, ensuring access to diagnostic facilities and integrating community-based surveillance networks. Early warning systems are essential for detecting and mitigating potential outbreaks.

:: Risk communication and community engagement are central to the fifth pillar. Transparent communication strategies and active community involvement are vital for building public trust and countering misinformation during health crises.

:: The final pillar focuses on monitoring population mobility to identify patterns that may influence disease transmission. Mapping these dynamics provides valuable insights for designing targeted public health interventions and allocating resources effectively...

.....
.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 07 Dec 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 07 Dec 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (6)

2024-12-06 / No. 49

[PDF of this issue](#)

- Preplanned Studies: Epidemiological Analysis of Tuberculosis Infection and Trend Changes — 152 Belt and Road Partner Countries, 2013–2021
- Preplanned Studies: Construction of a Competency Evaluation Indicator System for Emergency Response Staff in Disease Control and Prevention Institutions — China, 2023

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Organization Announcements

Paul G. Allen Frontiers Group [to 07 Dec 2024]

<https://alleninstitute.org/news-press/>

News

Featured

[The Paul G. Allen Family Foundation Awards \\$9 Million to new Allen Distinguished Investigators](#)

12.03.2024

Research funding will support six projects focused on how organelles within the cell communicate and cellular membrane form, function, and behavior.

BMGF - Gates Foundation [to 07 Dec 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

[European Union and the Bill & Melinda Gates Foundation to co-host Gavi High Level Pledging Summit](#)

5 December 2024

Bill & Melinda Gates Medical Research Institute [to 07 Dec 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications
No new digest content identified.

CARB-X [to 07 Dec 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 07 Dec 2024]

<http://cepi.net/>

CEPI News

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 07 Dec 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 07 Dec 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 07 Dec 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 07 Dec 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

01 December 2024

[**World AIDS Day 2024: Supporting innovative research to end inequality**](#)

Emory Vaccine Center [to 07 Dec 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 07 Dec 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 07 Dec 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Evidence Aid: Final farewell – 31 October 2024

www.evidenceaid.org

When we announced the news of our closure back in July, we hoped that Evidence Aid summaries would remain accessible and free of charge beyond closure of the charity. We are delighted to be able to announce that from now, the International Rescue Committee are hosting the website, evidenceaid.org and continue to make much of Evidence Aid's existing material available to the public. Should you have any questions relating to the website after 31 October, please contact airbel@rescue.org.

Fondation Merieux [to 07 Dec 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 07 Dec 2024]

<https://www.gavi.org/>

Press Releases

5 December 2024

Gavi Board approves measures to support sustainability of vaccine programmes and boost access in vulnerable communities

5 December 2024

Gavi's High-Level Pledging Summit 2025 to be co-hosted by the European Union and the Bill & Melinda Gates Foundation

4 December 2024

A decade after the deadliest Ebola outbreak in history, Sierra Leone begins a new chapter with nation-wide preventive vaccination of frontline workers

- Sierra Leone becomes the first country, among those most severely affected ten years ago by the West Africa Ebola outbreak, to launch nationwide preventive Ebola vaccination, targeting 20,000 frontline workers who will receive a single dose of Ebola vaccine

2 December 2024

Gavi, Save the Children and UNICEF collaborate to strengthen immunization services in Sudan

- Gavi will provide US\$ 23.4 million to support immunization for children living across Sudan, which hosts one of the largest displaced populations in the world
- The funding, provided via grants to UNICEF and Save the Children, is aimed at maintaining routine immunization, including through collaboration with local organizations to access hard-to-reach areas

- Since the outbreak of conflict in April 2023, over 70% of health facilities in affected areas have become non-operational, leaving more than 3 million children unprotected and vulnerable to vaccine-preventable diseases

GE2P2 Global Foundation [to 07 Dec 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – December 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 12 Nov 2024 – Issue 25](#)

GHIT Fund [to 07 Dec 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 07 Dec 2024]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 07 Dec 2024]

<https://www.glopid-r.org/news/>

News

[**GloPID-R Launches Coordinated Funding Mechanism to Strengthen Global Pandemic Preparedness, Global Research Improving Pandemic Preparedness \(GRIPP\)**](#)

December 4, 2024

Hilleman Laboratories [to 07 Dec 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 07 Dec 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 07 Dec 2024]

<https://www.humanimmunomeproject.org/>

News

[**Danaher Subsidiaries Provide Support to the Human Immunome Project, Advancing Global Effort to Map and Model Immune System**](#)

Danaher Subsidiaries Provide Support to the Human Immunome Project, Advancing Global Effort to Map and Model Immune System

NEW YORK, December 3, 2024 — Three subsidiaries of Danaher Corporation (“Danaher”), a leading global life sciences and diagnostics innovator, are supporting the nonprofit Human Immunome Project (HIP) with access to reagents, assays, and equipment. Danaher’s participation will help HIP to generate the world’s most comprehensive immunological dataset and provide a transformative new resource to the...

IAVI [to 07 Dec 2024]

<https://www.iavi.org/>

IAVI Report

TB vaccines: Achievable not aspirational

December 5, 2024

The 7th Global Forum on TB Vaccines stoked optimism but raised questions about how the field can optimize efforts to introduce new vaccines this decade.

Features

IAVI commemorates World AIDS Day in a landmark year for HIV prevention

December 2, 2024

Long-acting PrEP offers tremendous hope for prevention, but a vaccine remains necessary to end HIV as a public health threat.

INSERM [to 07 Dec 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

26 November 2024

ICMRA Rare Disease Workshop Report

26 November 2024

Facilitating Platform Clinical Trials During Global Public Health Emergencies

... This paper contains three main sections:

- Trial design and conduct considerations. This will include a discussion of key trial characteristics, such as developing protocol elements that need to be considered when conducting a platform trial during a pandemic, including specific design elements;
- Regulatory considerations including addressing certain perceived barriers and enablers;
- A brief discussion of certain lessons learnt from the COVID-19 pandemic.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 07 Dec 2024]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

6 December 2024

ICH Q9(R1) IWG Updated Q9(R1) Annex 1- Q8/Q9/Q10 Questions & Answers

The ICH Secretariat is pleased to announce the publication of the updated Q9(R1) Annex 1-Q8/Q9/Q10 Questions & Answers (R5). The ICH Assembly approved this updated Q9(R1) Annex 1 on 30 October 2024.

2 December 2024

[ICH M15 draft Guideline presentation available now on the ICH website](#)

The ICH M15 draft Guideline on General Principles for Model-Informed Drug Development reached Step 2b of the ICH Process on 6 November 2024 and entered the public consultation period.

ICRC [to 07 Dec 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 07 Dec 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 07 Dec 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 07 Dec 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

[Rethinking science: A mission-driven approach to tackle global sustainability challenges](#)

05 December 2024 - 4 min read

blogs / Reclaiming science as a human right

[Reclaiming science as a human right: Comment from the UN Special Rapporteur in the field of cultural rights](#)

03 December 2024

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

12th African Congress of Immunology (FAIS 2024)

Monday 9th December 2024

In December 2024, anticipated 300 delegates from the African Immunology community, including esteemed professionals, researchers, policymakers, and students, will convene in Cotonou, Benin,

IVAC [to 07 Dec 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 07 Dec 2024]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 07 Dec 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 07 Dec 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

South Sudan

[Urgent response needed to stop cholera outbreak in Upper Nile state](#)

Press Release 6 Dec 2024

Afghanistan

[Excluding women from medical institutes threatens the future of healthcare in Afghanistan](#)

Press Release 6 Dec 2024

Nigeria

[Levels of global acute malnutrition have doubled since last year in parts of northwest Nigeria](#)

Press Release 5 Dec 2024

Gaza-Israel war

[Three questions about the "apocalyptic" situation in Gaza](#)

Interview 3 Dec 2024

National Academy of Medicine - USA [to 07 Dec 2024]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 07 Dec 2024]

<https://www.nationalacademies.org/newsroom>

News

To Advance Women's Health Research, NIH Should Form New Institute and Congress Should Appropriate New Funding, Says Report

To address fundamental gaps in our knowledge about women's health, the National Institutes of Health should form a new institute focused on women's health research and Congress should appropriate new funding to support this research across the entire agency.

2024-12-05 *News Release*

National Vaccine Program Office - U.S. HHS [to 07 Dec 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 07 Dec 2024]

<http://www.nih.gov/>

News Releases

Friday, December 6, 2024

Single mutation in H5N1 influenza surface protein could enable easier human infection

NIH-funded study finds risk of human infection continues to remain low.

PATH [to 07 Dec 2024]

<https://www.path.org/media-center/>

Newsroom

Latest News & Press Releases

PATH and partners receive award for novel oral polio vaccine type 2 (nOPV2) project

December 5, 2024 by PATH

With more than a billion doses delivered so far, this next-generation oral polio vaccine is accelerating progress toward polio eradication.

Sabin Vaccine Institute [to 07 Dec 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

Press Releases

Sabin Vaccine Institute Announces Leadership Changes: Anuradha Gupta to step away; New members join Sabin Board of Trustees

December 5, 2024

Sabin Vaccine Institute's President for Global Immunization, Anuradha Gupta, is departing from full-time work after an impactful tenure during which she reshaped the organization's approach to immunization, championing locally led innovation and transdisciplinary partnerships.

In another significant leadership development, Sabin elected three distinguished members to its Board of Trustees to strengthen its R&D and global immunization portfolios...

As Sabin's programs continue to grow and deliver impact, three new members — Filip Dubovsky, Orin Levine, and Nadia Tornieporth — have joined its Board of Trustees. Each brings a wealth of experience and a shared commitment to advancing vaccines and global health...

UNAIDS [to 07 Dec 2024]

<http://www.unaids.org/en>

News, Stories, Updates

Feature story

Resilience amid crisis: strengthening the HIV response for displaced communities in Ethiopia

02 December 2024

UNICEF [to 07 Dec 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 04 December 2024

UNICEF appeals for US\$9.9 billion in humanitarian funding to support children affected by conflict and crisis in increasingly volatile world

GENEVA/NEW YORK, 5 December 2024 – UNICEF launched a US\$ 9.9 billion funding appeal today to reach 109 million children across 146 countries with lifesaving aid in 2025. The funds will be utilized in UNICEF’s humanitarian response to multiple conflicts, climate shocks, displacement, and health crises expected next...

Unitaid [to 07 Dec 2024]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 07 Dec 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 07 Dec 2024]

<https://www.vaccineacceptance.org/>

No new digest content identified.

Vaccine Confidence Project [to 07 Dec 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 07 Dec 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 07 Dec 2024]

<https://wellcome.org/news/all>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 07 Dec 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

December 3, 2024

Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer

PHILADELPHIA — (December 3rd, 2024) — The Wistar Institute's David B. Weiner, Ph.D. — Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distin...

World Bank [to 07 Dec 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

World Bank Approves \$250 Million for Türkiye to Improve Preparedness for Public Health Emergencies

December 5, 2024

WFPHA: World Federation of Public Health Associations [to 07 Dec 2024]

<https://www.wfpfa.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 07 Dec 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

WMA calls for ban on medical, nursing and midwifery training for women in Afghanistan to be lifted

05.12.2024

World Organisation for Animal Health [OIE] [to 07 Dec 2024]

<https://www.oie.int/>

Press Releases, Statements

No new digest content identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [to 07 Dec 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 07 Dec 2024]

<https://www.bio.org/press-releases>

Press Releases

New Report Finds Bioscience Sector Generates Over \$3 Trillion for U.S. Economy

December 2, 2024

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic performance, its impacts, and its geographic...

DCVMN – Developing Country Vaccine Manufacturers Network [to 07 Dec 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 07 Dec 2024]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 07 Dec 2024]

<https://ifpma.org/>

News, Statements [Selected]

Statement 4 Dec 2024

Statement on the revision of the Declaration of Helsinki on ethical principles for medical research

Statement 2 Dec 2024

Resumed 12th session of the Intergovernmental Negotiating Body (INB 12)

International Alliance of Patients' Organizations – IAPO [to 07 Dec 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

Marking 25 years of IAPO: a global alliance empowering patients' organisations

Wednesday, 4 December 2024

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 07 Dec 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases

AstraZeneca appoints Iskra Reic as Executive Vice President, International

04 December 2024

... encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.

Bavarian Nordic

Latest News - No new digest announcements identified

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases - No new digest announcements identified

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

For media and investors

05 December 2024

GSK and Zhifei revise and extend strategic vaccine collaboration in China

- Shingrix collaboration extended to 2034
- Expanded exclusive rights to explore collaboration with Zhifei on Arexvy

- Creates sustainable, long-term collaboration to bring innovative vaccines to more than 500 million people in China

04 December 2024

[First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines](#)

- Important steps to advance access to first single-dose malaria treatment, co-administered with chloroquine for radical cure, in endemic countries
- WHO prequalification and Guidelines for malaria include paediatric tafenoquine, responding to the disproportionate burden of relapsing malaria in children

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases

[Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study \(MOVE-NOW\) Evaluating LAGEVRIO™ \(molnupiravir; , an investigational oral antiviral COVID-19 medicine\) for the Treatment of COVID-19 in High-Risk Adults](#)

December 5, 2024

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Dec 4, 2024 Press release

Corporate and finance

[Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for \\$200 Million](#)

Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified [English translation function inoperable]

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

December 4, 2024

[Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal](#)

December 3, 2024

[Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®](#)

- Antibody levels remained high at 96% seroresponse in line with the two-year persistence data
- This long-lasting antibody persistence was comparable in older (65+) and younger adults

Vector State Research Centre of Virology and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - Website not responding at inquiry.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 12: E897-969 Dec 2024

<https://journalofethics.ama-assn.org/issue/evidence-based-design-health-care>

Evidence-Based Design in Health Care

Health care spaces and structures influence how efficiently and effectively health interventions work and for whom. Roles of clinical, common, and restricted areas in health care operations should be collectively and inclusively crafted to balance employees', patients', and visitors' needs for safety, comfort, collegiality, and good outcomes. Evidence-based design has evolved to guide architecture, engineering, building construction, and service delivery in health care. What is seen, heard, smelled, tasted, and felt when we inhabit health care spaces is neither clinically, ethically, nor aesthetically neutral because peace, calm, and rest facilitate healing. This theme issue considers evidence-based design ideas in health care that motivate good care

American Journal of Human Genetics

Dec 05, 2024 Volume 111 Issue 12 p2583-2848

<https://www.cell.com/ajhg/current>

Editors' Corner

This month in The Journal

Alyson B. Barnes, Kylee L. Spencer

Polygenic risk scores (PRS) could have a significant impact on disease prevention and management. Existing PRS perform poorly in diverse populations compared to European populations, a direct effect of the underrepresentation of individuals with diverse ancestries in genetic and genomic research, limiting applicability and raising concerns that clinical PRS use could widen healthcare disparities. In this issue, Kullo et al. introduce the Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium, established by the National Human Genome Research Institute and the National Cancer Institute to develop methods to improve the performance of PRS in individuals and populations of diverse genetic ancestry.

Year in review

Genomic medicine year in review: 2024

Teri A. Manolio, et al

Starting in 2019, AJHG has published an annual feature^{1,2,3,4,5} identifying ten key advances in applying genomic information to clinical care that were reported in the previous 12 months of published literature. The Genomic Medicine Working Group of the National Advisory Council for Human Genome Research of the National Human Genome Research Institute (NHGRI) has authored these reviews

based on its broader effort to identify notable accomplishments in genomic medicine on a monthly basis and posts them on a searchable website (see web resources)

Perspectives

The PRIMED Consortium: Reducing disparities in polygenic risk assessment

Iftikhar J. Kullo, et al. for the Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium
Open Access

To lessen health and healthcare disparities and extend advances in genomic medicine to all, the PRIMED Consortium is bringing together investigators and datasets from across the globe to develop PRS methods and improve their performance across diverse populations. We present Consortium objectives and design, ongoing activities, and initial products.

American Journal of Infection Control

December 2024 Volume 67 Issue 6 p803-988

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

American Journal of Preventive Medicine

November 2024 Volume 67 Issue 5 p641-802

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

January 2024 115(1)

<http://ajph.aphapublications.org/toc/ajph/current>

Displacements to Escape Natural Disasters In The United States

The January issue of *AJPH* focuses on the increasing prevalence of natural disaster-induced displacements within the United States. Featured articles explore disparities in the impact of these displacements and examine their prevalence and correlates. Other articles in this issue address naloxone distribution programs, urban reforestation efforts in Manhattan, the role of health monitoring data in relation to immigration and citizenship, and the use of long-acting reversible contraception.

American Journal of Tropical Medicine and Hygiene

Volume 111 (2024): Issue 6 (Dec 2024)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.111.issue-6.xml>

Articles

A Comprehensive Assessment of Quality of Antimalarial Medicines in Mainland Tanzania: Insights from Five Years of Postmarket Surveillance

Eulambius M. Mlugu, et al.

Routine Immunization Status and Factors Associated with Immunization Coverage among Children Aged 12–23 Months in Tanzania

Gumi Abdallah, et al.

Annals of Internal Medicine

November 2024 Volume 177, Issue 11

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 336 November 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/336/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 07 Dec 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 07 Dec 2024)

[Further analysis of determinants of Pentavalent and Measles immunizations dropouts among children under five years of age in Ethiopia from Mini-EDHS 2019](#)

Globally, immunization prevents an estimated 2–3 million deaths from illnesses that can be prevented by vaccination. The predictors of Pentavalent and Measles immunization dropout were not investigated suffi...

Authors: Moti Tolera, Abdi Birhanu, Lemma Demissie Regassa, Tamirat Getachew, Abraham Negash, Usmael Jibro, Alemayehu Deressa, Dureti Abdurahman, Aboma Motuma, Mulugeta Gamachu, Fethia Mohammed, Bikila Balis and Ibsa Mussa

Citation: *BMC Health Services Research* 2024 24:1527

Content type: Research Published on: 2 December 2024

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 07 Dec 2024)

[Evaluating COVID-19 impact, vaccination, birth registration, and underreporting in a predominantly indigenous population in Chiapas, Mexico](#)

Indigenous populations globally face significant health disparities compared to non-Indigenous groups, primarily due to marginalization and limited access to healthcare. In Mexico, which is home to the larges...

Authors: Elienai Joaquin-Damas, Svenn-Erik Mamelund, Benjamin M. Schnneider, Beatriz E. Sánchez-Hernández, Amanda Patishtán-López, Amanda Bleichrodt and Gerardo Chowell

Citation: *BMC Infectious Diseases* 2024 24:1376

Content type: Research Published on: 3 December 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 07 Dec 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 07 Dec 2024)
[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 07 Dec 2024)
[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 07 Dec 2024)

[When and why do people change their minds in favor of vaccination? Longitudinal analyses of switching COVID-19 vaccination preferences](#)

Vaccinations are a cornerstone of public health. However, reluctance to accepting vaccines is common. Using longitudinal data, we investigated which individual and contextual factors were associated with switc...

Authors: Floor Kroese, Wijnand van den Boom, Vincent Buskens, Pepijn van Empelen, Marlies Hulscher, Robert A. C. Ruiter, Daniëlle R. M. Timmermans, Marion de Vries, Marijn de Bruin and Mattijs Lambooi

Citation: BMC Public Health 2024 24:3392

Content type: Research Published on: 5 December 2024

[Information access and COVID-19 vaccination hesitancy among foreign-born persons in Sweden – a focus group interview-study](#)

In most countries, lower rates of COVID-19 vaccination have been observed in foreign-born individuals, yet little is known about the underlying reasons, especially as reported by these individuals themselves.

...

Authors: Mia Söderberg, Juhaina Swaid, Kristina Aurelius, Annika Rosengren, Kristina Jakobsson and Maria Magnusson

Citation: BMC Public Health 2024 24:3389

Content type: Research Published on: 5 December 2024

[Uptake of the hepatitis B vaccine among brothel-based female sex workers in Kampala, Uganda](#)

Hepatitis B is a significant health problem worldwide, particularly among high-risk groups such as female sex workers (FSWs). In Uganda, it is highly recommended that FSWs receive the hepatitis B vaccine. Howe...

Authors: Joana Nakiggala, Mathias Lwenge, Doreen Nakalembe, Bridget Nagawa Tamale, Aisha Nalugya, Jovan Galiwango, Junior Mike Wejuli, Kenneth Tebandeke, John Bosco Isunju, Richard K. Mugambe and Tonny Ssekamatte

Citation: BMC Public Health 2024 24:3380

Content type: Research Published on: 5 December 2024

[Adult influenza vaccination coverage before, during and after the COVID-19 pandemic in Canada](#)

Vaccination prevents seasonal influenza and its complications, particularly among high-risk populations. The COVID-19 pandemic has been reported to impact healthcare behaviors and vaccination patterns. This st...

Authors: Ruoke Chen, Nicolas L. Gilbert and Ève Dubé

Citation: BMC Public Health 2024 24:3357

Content type: Research Published on: 2 December 2024

Trends and inequalities in BCG immunisation coverage among one-year-olds in Sierra Leone, 2008–2019

Bacillus Calmette-Guérin (BCG) vaccination is a cornerstone of childhood immunisation programs, protecting against tuberculosis (TB), a major public health concern. Sierra Leone, a West African nation, faces c...

Authors: Augustus Osborne, Florence Gyembuzie Wongnaah, Camilla Bangura and Bright Opoku Ahinkorah

Citation: BMC Public Health 2024 24:3342

Content type: Research Published on: 30 November 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 07 Dec 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

December 2024 - Volume 29 - 6

<https://ebm.bmj.com/content/29/6>

[Reviewed earlier]

BMJ Global Health

December 2024 - Volume 9 - 12

<https://gh.bmj.com/content/9/12>

Commentary

Shaping a new era of global health for greater impact: CUGH 2024 highlights (5 December, 2024)

Beryne Odeny, et al.

Summary box

- Global health continues to grapple with tremendous inequities. There are growing concerns around inequities associated with technology and artificial intelligence (AI) to improve global health, epistemic injustice that leads to invalidation of Indigenous knowledge systems, and distribution of global health financing.
- We provide synthesis of some key themes from the 2024 Consortium of Universities for Global Health conference and also provide examples that highlight AI's detrimental and beneficial impacts, the integration of Indigenous knowledge into healthcare systems and the decolonisation of global health financing.
- This will inform future research, practice and policy, by highlighting more equitable and inclusive approaches to deploy AI, integrate Indigenous knowledge in healthcare and sustain global health financing.

Original Research

Ten-year health impact, economic impact and return on investment of the South African molecular diagnostics programme for HIV, tuberculosis and SARS-CoV-2 (3 December, 2024)

Brooke E Nichol

The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease (3 December, 2024)

Adrienne Marije de Roo

Bulletin of the World Health Organization

Volume 102(11); 2024 Nov 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/471305/>

Mpox and stigma

Bull World Health Organ. 2024 Dec 1; **102(12)**: 848–849. Published online 2024 Dec 1.

doi: 10.2471/BLT.24.021224

PMCID: PMC11601193

Mpox: an old disease poses a new threat

Nicaise Ndembi, Moréniké Oluwátóyìn Foláyan, Salim S Abdool Karim

Bull World Health Organ. 2024 Dec 1; 102(12): 844–844A. Published online 2024 Dec 1.

doi: 10.2471/BLT.24.292707

PMCID: PMC11601181

A risk- and needs-based strategy HIV prevention for adolescent girls and young women, WHO African Region

Sharana Mahomed, Elizabeth Bukusi, Izukanji Sikazwe, Philippa Musoke, Quarraisha Abdool Karim

Bull World Health Organ. 2024 Dec 1; 102(12): 913–915. Published online 2024 Nov 4.

doi: 10.2471/BLT.23.291160

PMCID: PMC11601182

Cell

Nov 27, 2024 Volume 187 Issue 24 p6785-7044

<https://www.cell.com/cell/current>

Featured Article

Using artificial intelligence to document the hidden RNA virosphere

Xin Hou, et al.

Open Access

A deep learning algorithm (LucaProt) that integrates both sequence and predicted structural information was employed to identify highly divergent RNA viral “dark matter” in 10,487 metatranscriptomes from diverse global ecosystems. A total of 161,979 potential RNA virus species and 180 RNA virus supergroups were unveiled using this artificial intelligence approach, including many understudied groups.

Child Care, Health and Development

Volume 50, Issue 6 November 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 116, Issue 5 Pages: 1143-1351 November 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

November 2024 Volume 46 Issue 11 p825-940

<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 21 Issue 6, December 2024
<https://journals.sagepub.com/toc/ctja/21/6>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 07 Dec 2024]
[No new digest content identified]

Contemporary Clinical Trials

Volume 146 November 2024
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/146/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 5 / October 2024
<https://www.liebertpub.com/toc/crispr/7/5>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023
<https://link.springer.com/journal/40142/volumes-and-issues/11-3>
[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 11 2024
<https://www.tandfonline.com/toc/icmo20/current>
[Reviewed earlier]

Current Opinion in Infectious Diseases

December 2024 - Volume 37 - Issue 6
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>
[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>
[Accessed 07 Dec 2024]
[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 3 Pages: 135-261 September 2024
<https://onlinelibrary.wiley.com/toc/14718847/current>
[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024
<https://www.tandfonline.com/toc/cdip20/34/6>
[Reviewed earlier]

Development Policy Review

Volume 42, Issue 6 November 2024
<https://onlinelibrary.wiley.com/toc/14677679/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>
[Reviewed earlier]

Disasters

Volume 48, Issue 4 October 2024
<https://onlinelibrary.wiley.com/toc/14677717/2024/48/4>
[Reviewed earlier]

EMBO Reports

Volume 25 Issue 12 6 December 2024
<https://www.embopress.org/toc/14693178/current>
Opinion 24 October 2024

[Scientific truth: an endangered species](#)

Frank Gannon

Academic research and selection panels need to deal with the problem of predatory journals as these are slowly but inevitably poisoning the scientific record.

Science & Society 12 November 2024

[Cultivating the next generation of leaders: How postdocs, principal investigators and institutes can nurture and select for leadership competencies](#)

James W Bryson, et al.

The transition from postdoc to PI is the most challenging career step. Peer groups, PIs and research institution can help postdocs to acquire the necessary skills and experience.

Emerging Infectious Diseases

Volume 30, Number 11—November 2024
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 48 September 2024

<https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 6 Pages: 1-35 November–December 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Data monitoring committee insights / Ethics reviews and AI tools

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 2 - Summer 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[New issue; No digest content identified]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 5, October 2024

<https://academic.oup.com/eurpub/issue/34/5>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

November/December 2024 Volume 103, Number 6

<https://www.foreignaffairs.com/issues/2023/103/6>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 3
<http://www.tandfonline.com/toc/sfds20/current>
[Reviewed earlier]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 07 Dec 2024]

Perspective Accepted on 06 Dec 2024

Gaps in the Ethical Governance of Pharmaceutical Clinical Trials in Europe

Rosemarie de la Cruz Bernabe, Shereen Cox, Christine Gispen-de Wied

Frontiers in Medicine doi 10.3389/fmed.2024.1507021

Policy and Practice Reviews Accepted on 02 Dec 2024

Biobanks and Data Interoperability in Latin America: Engendering High-Quality Evidence for the Global Research Ecosystem

Erick Valdés, Juan Alberto Lecaros

Frontiers in Medicine doi 10.3389/fmed.2024.1481891

Genetics in Medicines

Volume 26, Issue 12 December 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/12>

[New issue; No digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 07 Dec 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 5 October 29, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 07 Dec 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 07 Dec 2024]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 1, June 2024

<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>

SPECIAL SECTION – COMMEMORATING 30 YEARS

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 3 - July 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 9, November 2024

<https://academic.oup.com/heapol/issue/39/9>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 07 Dec 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 21-22 / November 2024

<https://www.liebertpub.com/toc/hum/35/21-22>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content
[Reviewed earlier]

Immunity

Nov 12, 2024 Volume 57 Issue 11 p2483-2704
<https://www.cell.com/immunity/current>
[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>
[Accessed 07 Dec 2024]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>
[Accessed 07 Dec 2024]
[No new digest content identified]

International Health

Volume 16, Issue 6, November 2024
<https://academic.oup.com/inthealth/issue/16/6>
[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 1 (Jun 2024):
<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>
Special Issue on Inter-State Communications
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 11 (2024): November 2024
<https://www.ijcmph.com/index.php/ijcmph/issue/view/118>
[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 5, October 2024
<https://academic.oup.com/ije/issue/53/5>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 4 2024
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>
Table of contents

[Reviewed earlier]

JAMA

December 3, 2024, Vol 332, No. 21, Pages 1771-1860

<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint

[Crossing the Equity Chasm - Addressing a Second Valley of Death in Biomedical Innovation](#)

Victor J. Dzau, MD; Emily L. Shambaugh, MPH; Melissa H. Laitner, PhD, MPH

JAMA. 2024;332(21):1781-1782. doi:10.1001/jama.2024.20677

This Viewpoint discusses how medical innovation often does not reach vulnerable populations, a lack that results in disparities in morbidity and mortality globally.

JAMA Health Forum

November 2024, Vol 5, No. 11

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

November 2024, Vol 178, No. 11, Pages 1089-1234

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

November 2024 - Volume 22 - Issue 11

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

November 2024 Volume 75 Issue 5 p691-844

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 6 December 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-6>

Original Paper

[Association of National Identity and Trust in Government with COVID-19 Vaccination and Brand Choice in Taiwan](#)

Chun-Tung Kuo, Ruoh-Rong Yu

24 March 2024 Pages: 967 - 976

Review of the Knowledge, Barriers, and Facilitators of HPV Vaccination among Latino Migrant and Seasonal Farmworkers in the United States

Sydney Hornberger, Niki Messmore, Ray Munguia-Vazquez

Review 04 July 2024 Pages: 1123 - 1131

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 11 (2024)

<https://www.cmro.in/index.php/jcmro/issue/view/89>

[Reviewed earlier]

Journal of Development Economics

Volume 172 January 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/172/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

November 2024 - Volume 78 - 11

<https://jech.bmj.com/content/78/11>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 3 Pages: 469-687 September 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 2 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: Climate Justice and the Global Development Crisis.

Guest Editors: Anna Malavisi, Tom Hilde, and Krushil Watene

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 4, November 2024

<https://muse.jhu.edu/issue/53739>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 5 October 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 8 Pages: 1-3156 November 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

November 2024 - Volume 50 - 11

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 274 November 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/274/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

November/December 2024 - Volume 30 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 3, September 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-3>

[Reviewed earlier]

Journal of the Royal Society – Interface

December 2024 Volume 21 Issue 221

<https://royalsocietypublishing.org/toc/rsif/current>

Research articles

Trade-off between the antiviral and vaccinal effects of antibody therapy in the humoral response to HIV

Soumya Mittal, et al.

Published:04 December 2024 Article ID:20240535 <https://doi.org/10.1098/rsif.2024.0535>

Antibody therapy for HIV-1 infection exerts two broad effects: a drug-like, antiviral effect, which rapidly lowers the viral load, and a vaccinal effect, which may control the viral load long-term by improving the immune response

Journal of Travel Medicine

Volume 31, Issue 7, October 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 98 • Number 11 • November 2024

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

The Lancet

Dec 07, 2024 Volume 404 Number 10469 p2223-2394, e7

<https://www.thelancet.com/journals/lancet/issue/current>

Health Policy

Strategic imperatives for health in the USA: a roadmap for the incoming presidential administration

Victor J Dzau, Melissa H Laitner, Emily L Shambaugh

Protecting the health of children with universal child cash benefits

H Luke Shaefer, Mona Hanna, David Harris, Dominic Richardson, Miriam Laker

The Lancet Child & Adolescent Health

Nov 2024 Volume 8 Number 11 p773-842, e16

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Nov 2024 Volume 6 Number 11 e772-e878

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Nov 2024 Volume 12 Number 11 e1737-e1909

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Nov 2024 Volume 24 Number 11 p1177-1286, e660-e724

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Nov 2024 Volume 9 Number 11 e831-e994

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Nov 2024 Volume 12 Number 11 p837-932, e65-e74

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 11 November 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-11>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 8, November 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 3 Pages: 517-821 September 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Dec 04, 2024 Volume 32 Issue 12 p4163-4534

<https://www.cell.com/molecular-therapy/current>

[New issue; No digest content identified]

Nature

Volume 636 Issue 8041, 5 December 2024

<https://www.nature.com/nature/volumes/635/issues/8041>

[New issue; No digest content identified]

Nature Biotechnology

Volume 42 Issue 11, November 2024

<https://www.nature.com/nbt/volumes/42/issues/11>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 07 Dec 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 11, November 2024

<https://www.nature.com/ng/volumes/56/issues/11>

[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 11, November 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/11>

[New issue; No digest content identified]

Nature Medicine

Volume 30 Issue 11, November 2024

<https://www.nature.com/nm/volumes/30/issues/11>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 11, November 2024

<https://www.nature.com/nrd/volumes/23/issues/11>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 11, November 2024

<https://www.nature.com/nrg/volumes/25/issues/11>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 11, November 2024

<https://www.nature.com/nri/volumes/24/issues/11>

[Reviewed earlier]

New England Journal of Medicine

Volume 391 No. 22 December 5, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

Perspective

Fight or Flight — Facing the Marburg Outbreak in Rwanda

J.P. Sibomana

NEJM Evidence

Volume 3 No. 12 December 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 07 Dec 2024]

[New issue; No digest content identified]

Pediatrics

Volume 154, Issue 6 December 2024

<https://publications.aap.org/pediatrics/issue/154/6>

Articles

Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children

David W. Hutton, PhD; Lisa A. Prosser, PhD; Angela M. Rose, MPH; Kerra Mercon, MS; Ismael R. Ortega-Sanchez, PhD ...

Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness

David W. Hutton, PhD; Lisa A. Prosser, PhD; Angela M. Rose, MPH; Kerra Mercon, MS; Ismael R. Ortega-Sanchez, PhD ...

PharmacoEconomics

Volume 42, Issue 11 November 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-11>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 07 Dec 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 07 Dec 2024)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 07 Dec 2024)

Improving HPV vaccine acceptance through peer-to-peer education among adolescent girls in the urban poor settings of Kisenyi, Kampala, Uganda

Doreen Tuhebwe, Christine Adyedo, Emmanuel Ahumuza, Steven Ssendagire, Rhoda K. Wanyenze
Research Article | published 05 Dec 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004007>

Essay

Technology transfer, intellectual property, and the fight for the soul of WHO

Melissa Barber melissa.barber@yale.edu

Published: December 5, 2024

<https://doi.org/10.1371/journal.pgph.0003940>

Abstract

Debates over the scope, terms, and governance of technology transfer—the sharing of essential technical information, know-how, and materials needed to manufacture a health product—are prominent and controversial in international health diplomacy. These debates have become focal points in recent contentious negotiations to amend the International Health Regulations (IHR) and draft a global Pandemic Agreement. While some countries advocate for automatic or compulsory mechanisms to facilitate access to health technologies, especially in times of crisis, others oppose legal frameworks that mandate non-voluntary participation by the pharmaceutical industry. Also at stake are questions of institutional mandate: the United States has amplified calls by industry that pandemic technology transfer policy should be the domain of the World Trade Organization (WTO) instead of the World Health Organization (WHO). This essay offers a counternarrative to claims that WHO is overstepping its historic role in global governance. Far from being a contemporary development, technology transfer was at the heart of WHO's work at its founding. WHO's early failure to secure antibiotic technology transfer in the face of US opposition led to its first major crisis, prompting the withdrawal of several member states. In response, WHO embarked in the 1950s on a visionary programme to establish a global network of non-profit, state-run drug manufacturers and scientists committed to the free exchange of knowledge. This ambitious initiative has been largely forgotten, excluded even from WHO's self-published accounts of historical technology transfer work. In the context of ongoing pandemic governance negotiations and the nascent mRNA hub program, remembering the lost vision of global solidarity embodied in WHO's midcentury technology transfer program offers a glimpse into an alternate path we might still chart, one where access to medicines is not bound by the logic of enforcing scarcity to maximize profit, and the right to health is a global responsibility.

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 07 Dec 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 07 Dec 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 07 Dec 2024]

[An exploration of the role of trust and rapport in enhancing vaccine uptake among Anishinaabe in rural northern Ontario](#)

Chris Sanders, Kristin Burnett, Lana Ray, Marina Ulanova, Donna M. Halperin, Scott A. Halperin, on behalf of the Canadian Immunization Research Network

Research Article | published 05 Dec 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0308876>

[Vaccine uptake, associated factors and reasons for vaccination status among the South African elderly; findings and next steps](#)

Mncengeli Sibanda, Rosemary J. Burnett, Brian Godman, Johanna C. Meyer

Research Article | published 04 Dec 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0314098>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 07 Dec 2024]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

December 3, 2024 vol. 121 no. 49

<https://www.pnas.org/toc/pnas/121/49>

[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 11, November 2024

<https://academic.oup.com/pnasnexus/issue/3/11>

Perspectives

[Complexity data science: A spin-off from digital twins](#)

Frank Emmert-Streib and others

PNAS Nexus, Volume 3, Issue 11, November 2024, pgae456,

<https://doi.org/10.1093/pnasnexus/pgae456>

Abstract

Digital twins offer a new and exciting framework that has recently attracted significant interest in fields such as oncology, immunology, and cardiology. The basic idea of a digital twin is to combine simulation and learning to create a virtual model of a physical object. In this paper, we explore how the concept of digital twins can be generalized into a broader, overarching field. From a theoretical standpoint, this generalization is achieved by recognizing that the duality of a digital twin fundamentally connects complexity science with data science, leading to the emergence of complexity data science as a synthesis of the two. We examine the broader implications of this field, including its historical roots, challenges, and opportunities.

Prehospital & Disaster Medicine

Volume 39 - Issue 3 - June 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 187 October 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/187/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

November 2024 Volume 291 Issue 2034

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 236 Pages 1-472 (November 2024)

<https://www.sciencedirect.com/journal/public-health/vol/236/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 17, Issue 3, November 2024

<http://phe.oxfordjournals.org/content/current>

Original Articles

[**Ethics of Mathematical Modeling in Public Health: The Case of Medical Male Circumcision for HIV Prevention in Africa**](#)
[Get access](#)

Stuart Rennie and others

Public Health Ethics, Volume 17, Issue 3, November 2024, Pages 125–138,

<https://doi.org/10.1093/phe/phae009>

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 6, November/December 2024

<https://journals.sagepub.com/toc/phrg/139/6>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 13, November 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 4, October 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 07 Dec 2024]

HPV vaccine knowledge, attitude, and programme satisfaction among parents and caregivers of vaccine recipients in Ogun state Nigeria

Human Papillomavirus is responsible for about 5% of the global cancer burden. In Nigeria, cervical cancer is the second most common cancer among women. The Federal Government of Nigeria and partners recently i...

Authors: Tope Olubodun, Elijah Ayowole Ogunsola, Marcellina Olutomi Coker, Surajudeen Adekunle Olayinka, Waheed Àlàmu Elegbede, Joke Oluwatoyin Ojedian, Kofoworola B. Olajide, Salimat Bola Sanni, Temitope Olawumi Oluwadare, Oluwaseun Temitope Inetago, Mobolanle Rasheedat Balogun, Onikepe Oluwadamilola Owolabi, Catherine Chidimma Anyadiegwu-Bello, Olukayode Abiodun Runsewe, Abiola Oluwatoyin Temitayo-Oboh, Tolulope Soyannwo...

Citation: *Reproductive Health* 2024 21:179

Content type: Research Published on: 4 December 2024

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

4 Dec 2024

Community participation and empowerment in primary health care in Latin America: an exploratory systematic review

Review | Spanish |

4 Dec 2024

Effects of the COVID-19 pandemic on the immunization program for children under 5 years of age in Ecuador

Original research | Spanish |

4 Dec 2024

Diagnostic accuracy of polymerase chain reaction for detection of mpox in humans

Review | English |

4 Dec 2024

Impact of prior dengue infection on severity and outcomes: meta-analysis of placebo-controlled trials

Original research | English |

4 Dec 2024

Ethical standards for research involving persons with mental disabilities pursuant to the Convention on the Rights of Persons with Disabilities: a proposal

Opinion and analysis | Spanish |

Risk Analysis

Volume 44, Issue 11 Pages: 2517-2754 November 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 07 Dec 2024]

[No new digest content identified]

Science

Volume 386| Issue 6726| 6 Dec 2024

<https://www.science.org/toc/science/current>

Editorial

[Science and America's challenge](#)

[Heather Wilson](#)

Today, more than at any time since World War II, the United States is being challenged scientifically on the global stage. Unfortunately, the nation is not meeting the moment. With a new administration in the wings, the country must begin to monitor scientific advancements to avoid technological surprise and develop strategies to close the critical technologies gap.

Despite a substantial increase in privately and publicly funded research over the past 30 years, Western democracies are losing the technology competition.//

Policy Forum

[Act on a mandate to protect research subjects' privacy](#)

BY Leslie E. Wolf, Natalie Ram

05 Dec 2024: 1096-109

Science and Engineering Ethics

Volume 30, Issue 6 December 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-6>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 776| 4 Dec 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 07 Dec 2024]

[No new digest content identified]

Social Science & Medicine

Volume 360 November 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/360/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 07 Dec 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 62 November–December 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/62/suppl/C>

Editorial Open access

[Public Health Challenges at the Upcoming Kumbh Mela 2025: Addressing the Mpox global public health emergency of international concern](#)

Avinash Sharma, Alfonso J. Rodriguez-Morales, Shruti Srivastava, Ziad A. Memish, Alimuddin Zumla
Article 102771

Tropical Medicine & International Health

Volume 29, Issue 12 Pages: i-iv, 991-1062 December 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

Vaccine

Volume 42, Issue 25 14 November 2024

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/25>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 07 Dec 2024]

Open Access Article

[Routine Immunization Microplanning Challenges and Opportunities in Low- and Middle-Income Countries: A Mixed-Method Landscape Analysis](#)

by Nicole Salisbury, Iqbal Hossain, Parysa Oskouipour, Audry Hong, Elan Ebeling, Jessica C. Shearer and Emily Grapa

Vaccines 2024, 12(12), 1370; <https://doi.org/10.3390/vaccines12121370> - 4 Dec 2024

Abstract

Background: Microplanning is widely recognized as a critical tool for improving immunization coverage and equity and is considered a core component of routine immunization. However, there is limited evidence on how microplans are developed and implemented and the effectiveness of microplanning

Open Access Article

Securing the Future: Strategies for Global Polio Vaccine Security Amid Eradication Efforts

by Vachagan Harutyunyan, Ann Ottosen, Rachel M. Burke, Derek Ehrhardt, Meredith Shirey, Rissa Durham and David Woods

Vaccines 2024, 12(12), 1369; <https://doi.org/10.3390/vaccines12121369> - 4 Dec 2024

Abstract

Background/Objectives: As we commemorate 50 years of the Expanded Programme on Immunization (EPI), the global mission to eradicate polio stands at a critical juncture. While remarkable progress has been made over the past decades, ensuring a steady supply of polio vaccines remains a [

Value in Health

December 2024 Volume 27 Issue 12 p1635-1804

<https://www.valueinhealthjournal.com/current>

Editorial

Rare Diseases: Economic Evaluation and Policy Considerations

Brian E. Rittenhouse, Elena Nicod

Published online: October 25, 2024 p1635-1636

Highlights

:: Accepted articles focus on documenting some of the challenges in rare disease evidence and economic evaluation and policy, as well as some ways in which the environment is evolving to try to address them.

:: Some of the suggested methods in these articles may solve some of these challenges and reduce the need for further initiatives because they may supply solutions to long-perceived difficulties in rare disease economic evaluation and policy.

:: Challenges will remain, however, because of the inherent difficulties in providing rare disease evidence and because proposed solutions challenge traditional approaches.

World Development

Volume 184 December 2024

<https://www.sciencedirect.com/journal/world-development/vol/184/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 07 Dec 2024]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

[No new digest content identified]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 07 Dec 2024]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 07 Dec 2024]

[Filter: All articles]

Real-World Effectiveness of Live Attenuated vs. Inactivated Influenza Vaccines in Children

Vera Rigamonti, Vittorio Torri, Shaun K Morris, Francesca Ieva, Carlo Giaquinto, Daniele Dona', Costanza Di Chiara, Anna Cantarutti

medRxiv 2024.12.04.24318492; doi: <https://doi.org/10.1101/2024.12.04.24318492>

Willingness to pay for COVID-19 vaccine and its correlates: A cross-sectional survey in Bangladesh

Mohammad Bellal Hossain, Md. Zakiul Alam, Md. Syful Islam, Shafayat Sultan, Md. Mahir Faysal, Sharmin Rima, Md. Anwer Hossain, Abdullah Al Mamun, Abdullah- Al- Mamun

medRxiv 2024.12.03.24318442; doi: <https://doi.org/10.1101/2024.12.03.24318442>

Where and how can WASH work? Understanding limited impacts from a randomized control trial of water, sanitation, and hygiene interventions in a high burden setting

Alicia N M Kraay, Andrew F Brouwer, Mondal H Zahid, Sammy Njenga, John M Colford Jr., Matthew C Freeman, Joseph NS Eisenberg

medRxiv 2024.12.03.24318379; doi: <https://doi.org/10.1101/2024.12.03.24318379>

Master protocols in Low-and-Middle income countries: A review of current use, limitations and opportunities for precision medicine

Luke Ouma, Sarah Al-Ashmori, Samuel Sarkodie, Lou Whitehead, Ann Breeze Konkoth, Shaun Hiu, Theophile Bigirimurame, Dorcas Kareithi, Jingky Lozano-Kuehne, Marzieh Shahmandi, James M. S Wason

medRxiv 2024.12.03.24318453; doi: <https://doi.org/10.1101/2024.12.03.24318453>

Abstract

Background: Master protocols - umbrella, basket and platform trials that study multiple therapies, multiple diseases or both, offer many advantages, most profoundly that they answer multiple treatment related questions, that would otherwise take multiple trials. We conducted a review of trial registries to characterise their use in advancing precision medicine in low and middle income countries (LMICs). Methods: We searched trial records available in 20 trial registries globally, including ClinicalTrials.gov and WHO ICTRP, to identify umbrella, basket and platform trials launched until 30 September 2023. Results: We identified 102 master protocols - 29 umbrella trials, 31 basket trials, 36 platform trials, as well as 6 other designs that partially aligned with the working definition of master protocols run in 54 different LMICs. Most trials were pharmaceutical industry-sponsored studies (60/102, 58.8%), conducted in oncology settings (56/102, 54.9%), currently ongoing (69/102, 67.6%) in early phase (phase I and II) settings (70/102, 68.6%). There was a greater representation of upper middle-income countries, particularly China that was a site to more than half of all master protocols

(53/102, 52%). Other common countries included Brazil, Russia, Turkey and Argentina. Most master protocols (93/102 91.2%) have been planned or launched in the last five years (2019 onwards), mainly with international collaborations in high-income countries. Only a small proportion of trials (5/102, 4.9%) launched exclusively in LMICs excluding China and European LMICs. For most studies, the statistical aspects of trial design and trial documentation (including study protocols and statistical analysis plans) were not publicly accessible. Conclusion: Unlike high-income countries, where several hundreds of master protocols are ongoing or completed, there is limited use of master protocols in LMICs, partly owing to low penetration of precision medicine research and limited clinical trial infrastructure in most LMICs. The evidence presented herein creates a case for supporting precision medicine initiatives in LMICs (especially Africa), and training and capacity building initiatives focused on innovative clinical trial designs like master protocols, especially in therapeutic areas outside oncology.

Characterising the 2023 chikungunya outbreak in Paraguay and the potential impact of a vaccine campaign

Pastor E Pérez-Estigarribia, Gabriel Ribeiro dos Santos, Simon Cauchemez, Cynthia Vazquez, Ana Karina Ibarrola-Vannucci, Guillermo Sequera, Shirley Villalba, María José Ortega, Jose Luis Di Fabio, Danny Scarponi, Christinah Mukandavire, Arminder Deol, Águeda Cabello, Elsi Vargas, Cyntia Fernández, Liz León, Henrik Salje

medRxiv 2024.12.02.24318291; doi: <https://doi.org/10.1101/2024.12.02.24318291>

Monkeypox in Europe: Epidemiology and Risk Factors – A Scoping Review Study

Nandakumar Ravichandran, Parnian Jalili

medRxiv 2024.08.28.24312706; doi: <https://doi.org/10.1101/2024.08.28.24312706> Revision

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 07 Dec 2024]

Study Protocol Open Access

Ethics of Procuring and Using Organs or Tissue from Infants and Newborns for Transplantation, Research, or Commercial Purposes: Protocol for a Bioethics Scoping Review

[version 1; peer review: awaiting peer review]

Maide Barış, Sebastian Porsdam Mann, Trung Nguyen, Jerry Menikoff, Dominic Wilkinson, Julian Savulescu jsavules@nus.edu.sg, Brian D. Earp bdearp@nus.edu.sg

Abstract

Since the inception of transplantation, it has been crucial to ensure that organ or tissue donations are made with valid informed consent to avoid concerns about coercion or exploitation. This issue is particularly challenging when it comes to infants and younger children, insofar as they are unable to provide consent. Despite their vulnerability, infants' organs and tissues are considered valuable for biomedical purposes due to their size and unique properties. This raises questions about the conditions under which it is permissible to remove and use these body parts for transplantation, research, or commercial purposes. The aim of this protocol is to establish a foundation for a scoping review that will identify, clarify, and categorise the main ethical arguments regarding the permissibility of removing and using organs or tissues from infants. The scoping review will follow the methodology outlined by the Joanna Briggs Institute (JBI), consisting of five stages: (1) identifying the research question, (2)

developing the search strategy, (3) setting inclusion criteria, (4) extracting data, and (5) presenting and analysing the results. We will include both published and unpublished materials that explicitly discuss the ethical arguments related to the procurement and use of infant organs or tissues in the biomedical context. The search will cover various databases, including the National Library of Medicine, Web of Science, EBSCO, and others, as well as grey literature sources. Two raters will independently assess the eligibility of articles, and data from eligible studies will be extracted using a standardised form. The extracted data will then be analysed descriptively through qualitative content analysis.

Research Article Open Access

REVISED - Public views of coronavirus science and scientists: findings from a cross-sectional survey

[version 2; peer review: 3 approved with reservations]

Rachael Gooberman-Hill R.Gooberman-Hill@bristol.ac.uk

Throughout the coronavirus pandemic, references to scientific findings have permeated public-facing communications. Understanding how members of the public view science, scientists and scientific uncertainty should enhance approaches to communication and individuals' decisions to engage with public health measures, including restrictions and vaccination programmes. This article provides descriptive statistics regarding public views and their univariable associations with key variables: age, gender, ethnicity, keyworker status, shielding status, caring responsibilities, and coronavirus exposure.

Study Protocol Open Access

Systems Policy Analysis for Antimicrobial Resistance Targeted Action (SPAARTA): A Research Protocol

[version 1; peer review: awaiting peer review]

Raheelah Ahmad, raheelah.ahmad@city.ac.uk et al.

The majority of countries (64%) have an Antimicrobial Resistance (AMR) National Action Plan (NAP V.1.0), but many remain unimplemented, and lack funding for interventions. Intervention selection requires a systematic approach to explain and predict progress. Looking beyond AMR is important to ensure the capture of systemic factors at the country level, which can impede or accelerate success.

* * * *

Think Tanks

Brookings [to 07 Dec 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 07 Dec 2024]

<https://www.cgdev.org/>

All Research

SPEECHES

Development Cooperation in a Contested World

Masood Ahmed

December 05, 2024

On December 5, 2024, CGD President Emeritus Masood Ahmed delivered a keynote address at the Australasian AID Conference at the Crawford School of Public Policy, Australian National University, Canberra, Australia.

Chatham House [to 07 Dec 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 07 Dec 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 07 Dec 2024]

<https://www.csis.org/>

Reports [Selected]

[Closing the Prevention Gap](#)

The development of long-acting PrEP methods makes it a pivotal moment for the global HIV response. Transforming HIV prevention will depend on ensuring a comprehensive set of PrEP options are available, affordable, and acceptable to populations vulnerable to the virus.

Brief by Katherine E. Bliss — December 3, 2024

Kaiser Family Foundation [to 07 Dec 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 07 Dec 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 07 Dec 2024]

<https://odi.org/en/publications/>

Publications [Selected]

[Transboundary adaption to climate change: governing flows of water, energy, food and people](#)

03 December 2024

Briefing/policy paper

Pew Research Center [to 07 Dec 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 07 Dec 2024]

<https://www.rand.org/pubs.html>
Published Research [Selected]
Journal Article Dec 2, 2024

The Value of Environmental Surveillance for Pandemic Response

Environmental sampling surveillance (ESS) systems can serve as an early warning system and support pandemic response. Using COVID-19 as a case study, the paper quantifies ESS's value for pandemic preparedness and response decisions.

Urban Institute [to 07 Dec 2024]
<https://www.urban.org/publications>
New Research Publications - Selected

World Economic Forum [to 07 Dec 2024]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

No new digest content identified.

*	*	*	*
*	*	*	*

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health,

human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*